Marshall Wace’s Niagen Bioscience NAGE Stock Holding History

Marshall Wace’s Portfolio NAGE Stock Details NAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-162,133	Closed	-$2.34M	–	3526
2025 Q2	$2.34M	Sell	162,133 -136,844	-46%	-$1.35M	﹤0.01%	1484
2025 Q1	$2.06M	Buy	+298,977	New	+$1.88M	﹤0.01%	1450
2024 Q3	–	Sell	-20,577	Closed	-$56.2K	–	3047
2024 Q2	$56.2K	Buy	+20,577	New	+$68.9K	﹤0.01%	2439
2023 Q2	–	Sell	-34,600	Closed	-$52.9K	–	3059
2023 Q1	$52.9K	Sell	34,600 -47,492	-58%	-$84.5K	﹤0.01%	2537
2022 Q4	$138K	Hold	82,092	–	–	﹤0.01%	2754
2022 Q3	$101K	Buy	82,092 +32,641	+66%	+$52.5K	﹤0.01%	3180
2022 Q2	$83K	Sell	49,451 -28,620	-37%	-$56K	﹤0.01%	3298
2022 Q1	$193K	Buy	+78,071	New	+$213K	﹤0.01%	3114
2021 Q4	–	Sell	-88,868	Closed	-$557K	–	4357
2021 Q3	$557K	Buy	88,868 +10,140	+13%	+$83.6K	﹤0.01%	2332
2021 Q2	$776K	Sell	78,728 -184,114	-70%	-$1.61M	﹤0.01%	1933
2021 Q1	$2.46M	Buy	+262,842	New	+$2.08M	0.01%	1214

Other funds holding NAGE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace's NAGE Position: Q3 2025 in Review

Marshall Wace sold out of Niagen Bioscience (NAGE) in Q3 2025, closing a stake of 162,133 shares — an estimated $2.34M sold.

Marshall Wace first reported a position in NAGE in Q1 2021 and held it in 11 quarters. The position peaked at $2.46M in Q1 2021. 162 funds tracked by Wall St. Rank hold NAGE as of Q3 2025.

Marshall Wace reported no remaining Niagen Bioscience position as of Q3 2025 after selling out during the quarter.
Marshall Wace sold 162,133 Niagen Bioscience shares in Q3 2025, an estimated $2.34M.
Marshall Wace first reported a position in Niagen Bioscience in Q1 2021 and held it in 11 quarters.
Marshall Wace's Niagen Bioscience position peaked at $2.46M in Q1 2021.
162 funds tracked by Wall St. Rank held Niagen Bioscience as of Q3 2025.

Based on Marshall Wace's 13F filing for Q3 2025, filed 13 Nov 2025.